Increased Stroke Risk: FDA May Limit Use of Anemia Drug Aranesp for Kidney Disease
WASHINGTON Oct 14 (Reuters) - U.S. health officials want advisers' input on the risks of anemia drugs made by Amgen Inc (AMGN.O) and Johnson & Johnson (JNJ.N) in certain chronic kidney disease patients, including how to adjust dosing and possible label changes.